Mavacoxib Explained

Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative jointdisease.^[1] It acts as a COX-2 inhibitor.^[2]

Mavacoxib, along with several other COX-2 selective inhibitors, including celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.^{[3] [4]}

Notes and References

1. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/000132/WC500069275.pdf European Public Assessment Report (EPAR): Trocoxil
2. Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, Marsh S, Fielder A, Stegemann MR . 6 . The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs . Journal of Veterinary Pharmacology and Therapeutics . 33 . 5 . 461–70 . October 2010 . 20840390 . 10.1111/j.1365-2885.2010.01165.x .
3. News: Langreth . Robert . vanc . The Chemical Cobbler . Forbes . June 23, 2003 .
4. Dr. John Talley: 2001 St. Louis Awardee. Chemical Bond. May 2001. 52. 5. 2. St. Louis Section, American Chemical Society. https://web.archive.org/web/20180415180802/http://www.stlacs.org/Bonds/2001May.pdf. 15 April 2018.